From GlobeNewswire: 2025-05-05 07:00:00

TG Therapeutics reported a first quarter 2025 net revenue of $119.7 million in the U.S. and raised its full-year global net revenue target to $575 million. The company also raised its full-year U.S. net revenue target to $560 million. Recent highlights include positive feedback on BRIUMVI treatment, ongoing innovation, and data presentations on BRIUMVI efficacy and safety. The company is focused on developing treatment options for individuals with MS and other autoimmune diseases. Financially, TG Therapeutics anticipates a strong second quarter with a target operating expense of approximately $300 million. The company remains committed to advancing its pipeline and meeting anticipated milestones for 2025. TG Therapeutics reported a net income of $5.1 million for the first quarter of 2025, a significant improvement from a net loss of $10.7 million in the same period last year. Cash, cash equivalents, and investment securities were $276.2 million as of March 31, 2025, providing sufficient funding for their business.

To discuss their financial results, TG Therapeutics will host a conference call on May 5, 2025, at 8:30 AM ET. Interested participants can join by calling 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.) with the conference title “TG Therapeutics.” A live webcast will also be available on the Company’s website.

BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IV is a novel monoclonal antibody designed to target CD20-expressing B-cells in adults with Relapsing Multiple Sclerosis (RMS). This treatment has proven effective in managing autoimmune disorders like RMS by depleting B-cells efficiently at low doses.

BRIUMVI comes with important safety information, including contraindications for patients with active Hepatitis B Virus infection or a history of severe infusion reactions. It is essential to monitor patients for infusion reactions and infections while considering the potential for increased immunosuppressive effects with this treatment.

Patients treated with BRIUMVI should be screened for Hepatitis B Virus before initiation, as reactivation could occur. Progressive Multifocal Leukoencephalopathy (PML) has been observed in patients treated with similar therapies, highlighting the need for careful monitoring and prompt action if PML is suspected.

Vaccinations should be administered according to guidelines, with live or live-attenuated vaccines given at least 4 weeks prior to starting BRIUMVI. The safety of immunization during or after treatment with BRIUMVI has not been fully studied, emphasizing the need for caution in this area. Vaccination with live virus vaccines is not recommended during treatment with BRIUMVI and until B-cell repletion. Infants of mothers treated with BRIUMVI during pregnancy should have B-cell counts assessed before receiving live vaccines. BRIUMVI may cause fetal harm, so pregnant women should take a pregnancy test before treatment. Decreased immunoglobulin levels were observed in BRIUMVI-treated patients. The most common adverse reactions were infusion reactions and upper respiratory tract infections. Physicians and healthcare professionals can find more information at www.briumvi.com.

Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system, affecting nearly 1 million people in the US. TG Therapeutics focuses on treatments for B-cell diseases and has received FDA approval for BRIUMVI in MS patients. The BRIUMVI Patient Support program is designed to aid US patients during treatment. For more information, visit www.tgtherapeutics.com. TG Therapeutics, Inc. reports revenue increase in Q1 2025, with $119,655 in product revenue and $1,201 in other revenue. Total revenue reached $120,856. Operating expenses totaled $112,234, resulting in a net income of $5,060. Cash, cash equivalents, and investment securities totaled $276,240 as of March 31, 2025.

Factors affecting TG Therapeutics’ actual results include commercialization success of BRIUMVI for RMS, revenue expectations, regulatory approvals, market demand, and pipeline milestones. Risks include maintaining commercial infrastructure, payor coverage, and post-approval compliance. Factors like regulatory changes, economic conditions, and research uncertainties could impact future performance.

TG Therapeutics’ financial data for Q1 2025 includes $119,655 in product revenue, $1,201 in other revenue, and total revenue of $120,856. Operating expenses amounted to $112,234, resulting in a net income of $5,060. As of March 31, 2025, cash, cash equivalents, and investment securities totaled $276,240, with total assets at $656,689. 1. A new study reveals that over 90% of plastic waste in the ocean comes from just 10 rivers, with the Yangtze River in China being the biggest contributor. This highlights the urgent need for countries to address plastic pollution at the source to protect marine life and ecosystems.

2. The World Health Organization reports that air pollution levels in many major cities exceed safe limits, with over 90% of the global population breathing polluted air. This poses serious health risks, leading to millions of premature deaths each year. Governments are urged to take action to improve air quality.

3. Researchers have discovered a new species of dinosaur in Argentina, named Llukalkan aliocranianus. This carnivorous dinosaur had a unique skull structure with large eyes and sharp teeth, providing new insights into the diversity of prehistoric creatures.

4. NASA’s Perseverance rover successfully landed on Mars, beginning its mission to search for signs of ancient life and collect samples for future return to Earth. This marks a major milestone in the exploration of the Red Planet and opens up new possibilities for scientific discovery.

5. The United Nations warns of a looming hunger crisis in Yemen, with over 16 million people facing food insecurity and malnutrition. Conflict, economic instability, and the COVID-19 pandemic have exacerbated the situation, leading to a critical need for humanitarian aid to prevent widespread starvation.



Read more at GlobeNewswire:: TG Therapeutics Reports First Quarter 2025 Financial